Botulinum toxin type A
Botulinum toxin type A is a neurotoxic protein produced by Clostridium botulinum and used clinically as a therapeutic agent.
Botulinum toxin type A is a neurotoxic protein produced by Clostridium botulinum and used clinically as a therapeutic agent. In medicine, it is best known for its ability to produce localized, reversible chemodenervation by blocking acetylcholine release at the neuromuscular junction. This mechanism reduces excessive muscle activity, which is why botulinum toxin type A is widely used in disorders characterized by involuntary muscle contraction or overactivity, including dystonia and spasticity.
As a therapy, botulinum toxin type A has an established role in symptom control rather than disease cure. Its effects are typically focal and temporary, making repeat treatment common in chronic conditions. In recent biomedical research, it continues to be evaluated not only for clinical efficacy and safety, but also for treatment patterns, durability of benefit, healthcare utilization, and economic impact in real-world practice.
Where the papers sit
9 papers from the last 6 months study Botulinum toxin type A directly · updated from PubMed 29 Oct 2026
Study type 3 clinical trials · 3 observational · 1 preclinical · 2 unclassified
Themes one subject
Those 9 are all about one subject.
-
Clinical Uses Across Disorders
Botulinum toxin treatment is being applied across spasticity, dystonia, migraine, neuropathic pain, bruxism and hypertrophic scars. Studies assess step-up dosing, treatment switching, healthcare costs, and comparisons with CGRP antibodies, dry needling, laser, or placebo. Mechanistic work links analgesia to suppressed CGRP release and altered NaV1.7 signaling. Evidence ranges from randomized trials to observational, real-world, and case-report data, without a single emerging treatment direction.
Papers
The 9 papers from the last 6 months that study Botulinum toxin type A directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Clinical Uses Across Disorders (9)
- Prospective observational study of step-up dose treatment with onabotulinumtoxinA in patients with spasticity. Journal of rehabilitation medicine · 28 Oct 2026 PMID 42949201
- Case Report: Botulinum Toxin Type A Injection for Bruxism Following Left Basal Ganglia Hemorrhage. The American journal of case reports · 10 Oct 2026 PMID 42855873
- Treatment of hypertrophic scars using fractional CO2 laser alone in comparison with adding botulinium toxin either intalesional injection or assisted drug delivery. Lasers in medical science · 2 Oct 2026 PMID 42825928
- OnabotulinumtoxinA for Painful Foot Dystonia in Parkinson Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Neurology. Clinical practice · 17 Sept 2026 PMID 42753227
- Botulinum toxin type A attenuates trigeminal neuralgia-like pain by suppressing CGRP release and modulating NaV1.7-associated signaling. The journal of headache and pain · 11 Aug 2026 PMID 42576205
- Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program. Cephalalgia : an international journal of headache · 2 Jul 2026 PMID 42390441
- Real-World Treatment Switch Rates, and Healthcare Costs of Botulinum Toxin Type A Among Patients with Cervical Dystonia in the USA: A Retrospective Claims Analysis. Neurology and therapy · 5 Jun 2026 PMID 42249235
- Real-World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9-Year Nationwide Analysis in France. Movement disorders clinical practice · 25 May 2026 PMID 42178762
- Spinal mechanisms and feasibility of Dry Needling versus Botulinum Toxin Type A in post-stroke lower limb spasticity: A proof-of-concept randomized clinical trial protocol (STROKE-POC). PloS one · 20 May 2026 PMID 42160369
By study type
Clinical trials (3)
- Treatment of hypertrophic scars using fractional CO2 laser alone in comparison with adding botulinium toxin either intalesional injection or assisted drug delivery. Lasers in medical science · 2 Oct 2026 PMID 42825928
- OnabotulinumtoxinA for Painful Foot Dystonia in Parkinson Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Neurology. Clinical practice · 17 Sept 2026 PMID 42753227
- Spinal mechanisms and feasibility of Dry Needling versus Botulinum Toxin Type A in post-stroke lower limb spasticity: A proof-of-concept randomized clinical trial protocol (STROKE-POC). PloS one · 20 May 2026 PMID 42160369
Observational studies and case reports (3)
- Prospective observational study of step-up dose treatment with onabotulinumtoxinA in patients with spasticity. Journal of rehabilitation medicine · 28 Oct 2026 PMID 42949201
- Case Report: Botulinum Toxin Type A Injection for Bruxism Following Left Basal Ganglia Hemorrhage. The American journal of case reports · 10 Oct 2026 PMID 42855873
- Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program. Cephalalgia : an international journal of headache · 2 Jul 2026 PMID 42390441
Preclinical: animal, cell and lab studies (1)
- Botulinum toxin type A attenuates trigeminal neuralgia-like pain by suppressing CGRP release and modulating NaV1.7-associated signaling. The journal of headache and pain · 11 Aug 2026 PMID 42576205
Unclassified: not yet indexed with MeSH (2)
- Real-World Treatment Switch Rates, and Healthcare Costs of Botulinum Toxin Type A Among Patients with Cervical Dystonia in the USA: A Retrospective Claims Analysis. Neurology and therapy · 5 Jun 2026 PMID 42249235
- Real-World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9-Year Nationwide Analysis in France. Movement disorders clinical practice · 25 May 2026 PMID 42178762
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-24. Last written: 2026-07-29 by GPT. Drafted by language models from published abstracts; not medical advice.